Dopamine D3 receptor antagonists.: 1.: Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans

被引:40
作者
Haadsma-Svensson, SR
Cleek, KA
Dinh, DM
Duncan, JN
Haber, CL
Huff, RM
Lajiness, ME
Nichols, NF
Smith, MW
Svensson, KA
Zaya, MJ
Carlsson, A
Lin, CH
机构
[1] Pharmacia, Struct Analyt & Med Chem, Kalamazoo, MI 49007 USA
[2] Univ Gothenburg, Dept Pharmacol, Gothenburg, Sweden
关键词
D O I
10.1021/jm010145w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
5,6-Dimethoxy-2-(N-dipropyl)-aminoindan (3, PNU-99194A) was found to be a selective dopamine D-3 receptor antagonist with potential antipsychotic properties in animal models. To investigate the effects of nitrogen substitution on structure-activity relationships, a series of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans were synthesized and evaluated in vitro for binding affinity and metabolic stability. The results indicate that substitution at the amine nitrogen of the 2-aminoindans is fairly limited to the di-N-propyl group in order to achieve selective D-3 antagonists. Thus, combinations of various alkyl groups were generally inactive at the D-3 receptor. Although substitution with an N-alkylaryl or N-alkylheteroaryl group yields compounds with potent D-3 binding affinity, the D-2 affinity is also enhanced, resulting in a less than 4-fold preference for the D-3 receptor site, and no improvements in metabolic stability were noted. A large-scale synthesis of the D-3 antagonist 3 has been developed that has proven to be reproducible with few purification steps. The improvements include the use of 3,4-dimethoxybenzaldehyde as a low-cost starting material to provide the desired 5,6-dimethoxy-1-indanone 5c in good overall yield (65%) and the formation of a soluble silyl oxime 17 that was reduced efficiently with BH3. Me2S. The resulting amino alcohol was alkylated and then deoxygenated using a Lewis acid and Et3SiH to give the desired product 3 in good overall yield of (similar to 65%) from the indanone 5c.
引用
收藏
页码:4716 / 4732
页数:17
相关论文
共 40 条
[1]  
ASLINGTON MG, 1976, TETRAHEDRON LETT, V17, P2955
[2]  
Audinot V, 1998, J PHARMACOL EXP THER, V287, P187
[3]  
Baker LE, 1997, BEHAV PHARMACOL, V8, P243
[4]  
CAINE SB, 1995, BEHAV PHARMACOL, V6, P333
[5]   CONFORMATIONALLY RESTRICTED CONGENERS OF DOPAMINE DERIVED FROM 2-AMINOINDAN [J].
CANNON, JG ;
PEREZ, JA ;
BHATNAGAR, RK ;
LONG, JP ;
SHARABI, FM .
JOURNAL OF MEDICINAL CHEMISTRY, 1982, 25 (12) :1442-1446
[6]  
CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140
[7]   Neurotransmitter interactions in schizophrenia - Therarpeutic implications [J].
Carlsson, A ;
Waters, N ;
Carlsson, ML .
BIOLOGICAL PSYCHIATRY, 1999, 46 (10) :1388-1395
[8]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[9]  
CHIO CL, 1994, MOL PHARMACOL, V45, P51
[10]   Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach [J].
Clifford, JJ ;
Waddington, JL .
PSYCHOPHARMACOLOGY, 1998, 136 (03) :284-290